Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
Cell Therapy Institute, Center for Collaborative Research, Nova Southeastern University, Fort Lauderdale, FL, USA.
Clin Oral Investig. 2017 Sep;21(7):2265-2272. doi: 10.1007/s00784-016-2019-5. Epub 2016 Dec 1.
Dimensional changes of the alveolar bone following tooth extraction are a major challenge in daily dental practice. To limit bone loss, a variety of biomaterials including bone grafts, barrier membranes, and growth factors have been utilized either alone or in combination therapies to increase the speed and quality of new bone formation. The aim of the present in vitro study was to investigate the regenerative potential of Osteogain®, a new liquid carrier system of enamel matrix derivative (EMD) in combination with an absorbable collagen sponge (ACS) specifically designed for extraction socket healing.
The potential of ACS was first investigated using ELISA to quantify total amelogenin adsorption and release from 0 to 10 days. Thereafter, the cellular effects of ST2 pre-osteoblasts were investigated for cellular attachment at 8 h and cell proliferation at 1, 3, and 5 days as well as osteoblast differentiation by real-time PCR and alizarin red staining for cells seeded on (1) tissue culture plastic, (2) ACS alone, and (3) ACS + Osteogain®.
ACS efficiently loaded nearly 100% of the amelogenin proteins found in Osteogain® which were gradually released up to a 10-day period. Osteogain® also significantly induced a 1.5-fold increase in cell attachment and resulted in a 2-6-fold increase in mRNA levels of osteoblast differentiation markers including runt-related transcription factor 2 (Runx2), collagen1a2, alkaline phosphatase, and bone sialoprotein as well as induced alizarin red staining when combined with ACS.
In summary, these findings suggest that Osteogain® is capable of inducing osteoblast attachment and differentiation when combined with ACS. Future animal studies and randomized human clinical trials are necessary to further support these findings.
The use of Osteogain® in combination with ACS may provide a valuable means to limit dimensional changes following tooth extraction.
拔牙后牙槽骨的尺寸变化是日常牙科实践中的主要挑战。为了限制骨丢失，已经使用了各种生物材料，包括骨移植物、屏障膜和生长因子，单独或联合治疗以增加新骨形成的速度和质量。本体外研究的目的是研究 Osteogain®的再生潜力，Osteogain®是一种新的釉基质衍生物（EMD）液体载体系统，与专门设计用于拔牙窝愈合的可吸收胶原海绵（ACS）联合使用。
首先使用 ELISA 定量分析从 0 天到 10 天 ACS 对总釉原蛋白的吸附和释放，以评估 ACS 的潜力。此后，通过实时 PCR 和茜素红染色研究 ST2 前成骨细胞的细胞效应，以评估细胞附着在（1）组织培养塑料、（2）ACS 单独和（3）ACS+Osteogain®上的情况，细胞增殖在 1、3 和 5 天，以及成骨细胞分化。
ACS 有效地负载了 Osteogain®中发现的近 100%的釉原蛋白，这些蛋白在 10 天的时间内逐渐释放。Osteogain®还显著诱导细胞附着增加 1.5 倍，并导致成骨细胞分化标志物 runt 相关转录因子 2（Runx2）、胶原 1a2、碱性磷酸酶和骨涎蛋白的 mRNA 水平增加 2-6 倍，并与 ACS 结合时诱导茜素红染色。
总之，这些发现表明，当与 ACS 结合使用时，Osteogain®能够诱导成骨细胞附着和分化。需要进一步的动物研究和随机临床试验来进一步支持这些发现。
Osteogain®与 ACS 联合使用可能是限制拔牙后尺寸变化的一种有价值的方法。
